These data provide a rationale for considering mTOR inhibitors and broad multi-targeted TKIs for the ongoing I-SPY 2.2 block design to target these pathways in patients with these tumor signatures who do not achieve pCR and have worse DRFS. This evidence concerns the gene MTOR and neoplasm.